Because BQ-mediated APP induction does not require interferon signaling, this strategy may have particular relevance for clinical scenarios in which tumor antigen presentation is dampened by the loss or silencing of cancer cell interferon signaling, which has been demonstrated to confer both intrinsic 59 and acquired 23 ICB resistance in human melanoma patients. This evidence concerns the gene APP and neoplasm.